Pharmidex Announcement: Dr. Christopher Ireson’s New Role
January 28, 2025
We are excited and proud to share that our Head of Oncology, Dr. Christopher Ireson, has been named as a member of the Translational Advisory Board of the Brain Tumour Charity! 🧠💼
Dr. Ireson’s extensive expertise in oncology will help drive impactful scientific advancements and translational research to improve outcomes for brain tumour patients. We are incredibly grateful to have such a talented leader in our team contributing to this important cause. 🌟
Please join us in congratulating Dr. Ireson on this achievement! 👏
#Pharmidex #Oncology #TranslationalResearch #BrainTumourCharity #ProudMoment #ScientificAdvisoryBoard
At Pharmidex , we deliver high-quality LC-MS bioanalysis to support drug development across a wide range of analysis. Our experienced team supports preclinical, translational and clinical studies, providing accurate, reliable data under GLP and GCP to help drive confident decision-making. Learn more about our LC-MS capabilities: https://www.pharmidex.com/Discovery-Bioanalysis
Pharmidex offers high-quality Clinical Chemistry services delivering accurate, reliable data to support drug development. Our expert team and robust, quality-driven workflows enable trusted results that help accelerate decision-making and strengthen collaboration with pharma companies, CROs and academic partners. By working together, we support better science and more efficient drug development. 👉 Learn more: https://www.pharmidex.com/Clinical-chemistry
Pharmidex is delighted to share that Ash Alavijeh , Head of Operations, will be attending the UK BioIndustry Association (BIA) Annual Gala Dinner at the Roundhouse, London. Ash is looking forward to connecting with pharma and biotech colleagues to explore new collaborations, partnerships, and opportunities, all with the shared goal of advancing drug discovery and development. If you’re attending, feel free to connect with Ash this evening.
